News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis AG (JOBS) Takes $235 Million Charge After Stopping Trial
August 29, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Reuters) - Novartis AG stopped development of its Aurograb treatment for bacterial infections after it showed a lack of efficacy in mid-stage trials, and said it would take a $235 million impairment charge.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
Novartis
MORE ON THIS TOPIC
Insights
From Nuclear Winter to Renewal: Biotech Investing for 2026
January 8, 2026
·
1 min read
·
Jennifer Smith-Parker
Rare diseases
Crinetics Advances Potential Neurocrine Competitor With Fresh Data and Money
January 7, 2026
·
2 min read
·
Dan Samorodnitsky
Infectious disease
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
January 7, 2026
·
2 min read
·
Tristan Manalac
Stomach cancer
Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer
January 7, 2026
·
2 min read
·
Tristan Manalac
